Osteoporosis: Yesterday, today and tomorrow

Rheumatology

Volumn 50, Issue 7, 2011, Pages 1181-1183

  Lane, Nancy E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; FIBROBLAST GROWTH FACTOR 2; ODANOCATIB; PARATHYROID HORMONE[1-34]; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

BONE DENSITY; BONE STRENGTH; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; HIP FRACTURE; HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL;

ABSORPTIOMETRY, PHOTON; AGE DISTRIBUTION; AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FORECASTING; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS; PROGNOSIS; SEX DISTRIBUTION;

EID: 79959403007     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker147     Document Type: Editorial

References (15)

1. Kanis JA, Melton LJ 3rd, Christiansen C, Johnson CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
2. Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010;363:2027-35.
3. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with steoporosis. N Engl J Med 2001;344:1434-41.
4. Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoidinduced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 2004;89:3332-6.
5. Wu X, Pang L, Lei W et al. Inhibition of Sca-1 positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone n bone remodeling. Cell stem Cell 2010;7:571-80.
6. Wassertheil-Smoller S, Hendrix SL, Limacher M et al. WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84.
7. Black DM, Schwartz AV, Ensrud KE et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38.
8. Shane E, Burr D, Ebeling PR et al. American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94.
9. Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX and its applications to clinical practice. Bone 2009;44:734-43.
10. Cummings SR, San Martin J, McClung MR et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
11. Bone HG, McClung MR, Roux C et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low one density. J Bone Miner Res 2010;25:937-47.
12. Li X, Ominsky MS, Warmington KS et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24:578-88.
13. Yao W, Guan M, Liu R et al. ASBMR abstract. Directing mesenchymal stem cells to bone to increase bone formation or reversing osteoporosis by directing mesenchymal stem cells to the bone surface. J Bone Miner Res 2010;(Suppl. 1):42.
14. Annweiler C, Montero-Odasso M, Schott AM, Berrut G, Fantino B, Beauchet O. Fall prevention and vitamin D in the elderly: an overview of the key ole of the non-bone effects. J Neuroeng Rehabil 2010;7:50.
15. McKay C, Anderson KE. How to manage falls in community dwelling older adults: a review of the evidence. Postgrad Med J 2010;86:299-306.